Structure-Activity Study of N -((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H -indole-2-carboxamide (SB269652), a Bitopic Ligand That Acts as a Negative Allosteric Modulator of the Dopamine D2 Receptor

Journal of Medicinal Chemistry

Volumn 58, Issue 13, 2015, Pages 5287-5307

  Shonberg, Jeremy ^a,b   Draper Joyce, Christopher ^a   Mistry, Shailesh N ^a,c   Christopoulos, Arthur ^a   Scammells, Peter J ^a   Lane, J Robert ^a   Capuano, Ben ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3. 2,3,4,5 TETRAHYDRO 1H BENZO[C]AZEPIN 1 ONE; 4.2,3,4,5 TETRAHYDRO 1H BENZO[C]AZEPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; N [( TRANS) 4 [2 (3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; N [(TRANS) 4 [2 (7 CYANO 3,4 DIHYDROISOQUINOLIN 2 (1H)YL)CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; N [TRANS 4 [2 (4,5 DIHYDRO 1H BENZO[ C ]AZEPIN 2 (3H)YL)ETHYL]CYCLOHEXYL] 1H INDOLE CARBOXAMIDE; N [TRANS 4 [2 (6,7 DIHYDROTHIENO[3,2 C ]PYRIDIN 5 (4H )YL)ETHYL]CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; N [TRANS 4 [2 (7 BROMO 3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; N [TRANS 4 [2 (7 CHLORO 3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; N [TRANS 4 [2 (7 FLUORO 3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; N [TRANS 4 [2 [7 (TRIFLUOROMETHYL) 3,4 DIHYDROISOQUINOLIN 2 (1H)YL)ETHYL]CYCLOHEXYL] 1H INDOLE 2 CARBOXAMIDE; TERT BUTYL [( TRANS ) 4 [2 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [(TRANS ) 4 [2 (6,7 DIHYDROTHIENO[3,2 C ]PYRIDIN 5 (4H)YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [(TRANS) 4 [2 (3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [TRANS 4 [2 (4 (2 METHOXYPHENYL)PIPERAZIN 1 YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [TRANS 4 [2 (4,5 DIHYDRO 1H BENZO[C]AZEPIN 2 (3H )YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [TRANS 4 [2 (7 (TRIFLUOROMETHYL) 3,4 DIHYDROISOQUINOLIN 2 (1H)YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [TRANS 4 [2 (7 BROMO 3,4 DIHYDROISOQUINOLIN 2 (1H)YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [TRANS 4 [2 (7 CHLORO 3,4 DIHYDROISOQUIN 2 (1H)YL)ETHYL]CYCLOHEXYL]CARBAMATE; TERT BUTYL [TRANS 4 [2 (7 FLUORO 3,4 DIHYDROISOQUINOLIN 2 (1H)YL)ETHYL]CYCLOHEXYL]CARBAMATE; TRANS 4 [2 (3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXANAMINE DIHYDROCHLORIDE; TRANS 4 [2 (4 (2 METHOXYPHENYL)PIPERAZIN 1 YL)ETHYL]CYCLOHEXAN 1 AMINE TRIHYDROCHLORIDE; TRANS 4 [2 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL)ETHYL]CYCLOHEXAN 1 AMINE TRIHYDROCHLORIDE; TRANS 4 [2 (4,5 DIHYDRO 1H BENZO[ C ]AZEPIN 2 (3H)YL)ETHYL]CYCLOHEXANAMINE; TRANS 4 [2 (6,7 DIHYDROTHIENO[3,2 C]PYRIDIN 5 (4H)YL)ETHYL]CYCLOHEXANAMINE; TRANS 4 [2 (7 (TRIFLUOROMETHYL) 3,4 DIHYDROISOQUINOLIN 2 (1H)YL)ETHYL]CYCLOHEXANAMINE; TRANS 4 [2 (7 BROMO 3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXANAMINE; TRANS 4 [2 (7 CHLORO 3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXANAMINE; TRANS 4 [2 (7 FLUORO 3,4 DIHYDROISOQUINOLIN 2 (1H )YL)ETHYL]CYCLOHEXANAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1H-INDOLE-2-CARBOXYLIC ACID (4-(2-(CYANO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)ETHYL)CYCLOHEXYL)AMIDE; DOPAMINE 2 RECEPTOR; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; LIGAND; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RACLOPRIDE;

ALKYLATION; ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL MEMBRANE; CHO CELL LINE; COMPETITIVE BINDING ASSAY; COMPETITIVE INHIBITION; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HYDROGEN BOND; IONIZATION; NONHUMAN; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; HUMAN; METABOLISM; PROTEIN CONFORMATION; RADIOASSAY;

ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETULUS; HUMANS; HYDROGEN BONDING; INDOLES; ISOQUINOLINES; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937510650     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00581     Document Type: Article

References (56)

1. Davis, K. L.; Kahn, R. S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: A review and reconceptualization Am. J. Psychiatry 1991, 148, 1474-1486
2. 2 receptor in schizophrenia Expert Opin. Ther. Targets 2006, 10, 515-531
3. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 2009, 8, 41-54
4. Christopoulos, A. Advances in G protein-coupled receptor allostery: from function to structure Mol. Pharmacol. 2014, 86, 463-478
5. Keov, P.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors: A pharmacological perspective Neuropharmacology 2011, 60, 24-35
6. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51
7. Wootten, D.; Christopoulos, A.; Sexton, P. M. Emerging paradigms in GPCR allostery: implications for drug discovery Nat. Rev. Drug Discov. 2013, 12, 630-644
8. Kapur, S.; Zipursky, R.; Jones, C.; Remington, G.; Houle, S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia Am. J. Psychiatry 2000, 157, 514-520
9. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66
10. Valant, C.; Lane, J. R.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 153-178
11. Mohr, K.; Tränkle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise Br. J. Pharmacol. 2010, 159, 997-1008
12. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat J. Med. Chem. 2000, 43, 1878-1885
13. 2 receptors Mol. Pharmacol. 2010, 78, 925-934
14. 4-selective drugs: probes, models and candidates Trends Pharmacol. Sci. 2011, 32, 148-157
15. 3 receptor antagonist, SB-277011-A J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165
16. Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders Chem. Rev. 2007, 107, 274-302
17. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Methods in Neurosciences; Stuart, C. S., Ed.; Academic Press: San Diego, CA, 1995; Vol. 25, pp 366-428.
18. 3 receptor J. Med. Chem. 2012, 55, 6689-6699
19. 3 selective antagonist Science 2010, 330, 1091-1095
20. Lane, J. R.; Donthamsetti, P.; Shonberg, J.; Draper-Joyce, C. J.; Dentry, S.; Michino, M.; Shi, L.; López, L.; Scammells, P. J.; Capuano, B.; Sexton, P. M.; Javitch, J. A.; Christopoulos, A. A new mechanism of allostery in a G protein-coupled receptor dimer Nat. Chem. Biol. 2014, 10, 745-752
21. Milligan, G. G protein-coupled receptor dimerization: Function and ligand pharmacology Mol. Pharmacol. 2004, 66, 1-7
22. Guo, W.; Urizar, E.; Kralikova, M.; Mobarec, J. C.; Shi, L.; Filizola, M.; Javitch, J. A. Dopamine D2 receptors form higher order oligomers at physiological expression levels EMBO J. 2008, 27, 2293-2304
23. 2 receptor dimerization Mol. Brain 2010, 3, 25
24. Smith, N. J.; Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Pharmacol. Rev. 2010, 62, 701-725
25. Armstrong, D.; Strange, P. Dopamine D2 receptor dimer formation: evidence from ligand binding J. Biol. Chem. 2001, 276, 22621-22629
26. 2 receptor dimers in human and rat brain FEBS Lett. 1998, 441, 383-386
27. 2 affinity and potency ACS Med. Chem. Lett. 2012, 3, 991-996
28. 2 receptor ligands: Synthesis and binding properties J. Med. Chem. 2011, 54, 4896-4903
29. 3 receptor antagonists: A medicinal chemistry perspective ChemMedChem 2011, 6, 1152-1162
30. 2 receptor J. Med. Chem. 2013, 56, 9199-9221
31. Crosby, I. T.; Shin, J. K.; Capuano, B. The application of the schmidt reaction and beckmann rearrangement to the synthesis of bicyclic lactams: Some mechanistic considerations Aust. J. Chem. 2010, 63, 211-226
32. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 2007, 28, 382-389
33. Christopoulos, A. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log Trends Pharmacol. Sci. 1998, 19, 351-357
34. Bondi, A. van der Waals volumes and radii J. Phys. Chem. 1964, 68, 441-451
35. Ingold, C. K. Structure and Mechanism in Organic Chemistry; Cornell University Press: Ithaca, NY, 1953; pp 67-72.
36. Voth, A. R.; Khuu, P.; Oishi, K.; Ho, P. S. Halogen bonds as orthogonal molecular interactions to hydrogen bonds Nat. Chem. 2009, 1, 74-79
37. Politzer, P.; Murray, J. S.; Clark, T. Halogen bonding: an electrostatically-driven highly directional noncovalent interaction Phys. Chem. Chem. Phys. 2010, 12, 7748-7757
38. Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles and applications of halogen bonding in medicinal chemistry and chemical biology J. Med. Chem. 2013, 56, 1363-1388
39. 2 receptor J. Med. Chem. 2014, 57, 4924-4939
40. 4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding J. Med. Chem. 2009, 52, 4923-4935
41. Shonberg, J.; Lopez, L.; Scammells, P. J.; Christopoulos, A.; Capuano, B.; Lane, J. R. Biased agonism at G protein-coupled receptors: The promise and the challenges - a medicinal chemistry perspective Med. Res. Rev. 2014, 34, 1286-1330
42. 2 receptor subtype selectivity J. Med. Chem. 2014, 57, 7042-7060
43. 3 receptor antagonists Bioorg. Med. Chem. Lett. 2003, 13, 2179-2183
44. 3 receptor antagonists J. Med. Chem. 2009, 52, 2559-2570
45. 1 receptor J. Med. Chem. 2010, 53, 3028-3037
46. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands targeting GPCRs ChemMedChem 2011, 6, 963-974
47. Portoghese, P. S. 2000 Alfred Burger Award Address in Medicinal Chemistry. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 2001, 44, 3758-3758
48. Berque-Bestel, I.; Lezoualch, F.; Jockers, R. Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers Curr. Drug Discovery Technol. 2008, 5, 312-318
49. Mammen, M.; Choi, S.-K.; Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors Angew. Chem., Int. Ed. 1998, 37, 2754-2794
50. Kenakin, T. What is pharmacological "affinity" ? Relevance to biased agonism and antagonism Trends Pharmacol. Sci. 2014, 35, 434-441
51. Onaran, H. O.; Rajagopal, S.; Costa, T. What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling Trends Pharmacol. Sci. 2014, 35, 639-647
52. Bordwell, F. G. Equilibrium acidities in dimethyl sulfoxide solution Acc. Chem. Res. 1988, 21, 456-463
53. Mérour, J.-Y.; Joseph, B. Synthesis and reactivity of 7-azaindoles (1 H -pyrrolo[2,3- b ]pyridine) Curr. Org. Chem. 2001, 5, 471-506
54. 3 (X = F, Cl) complexes ChemPhysChem 2014, 15, 109-117
55. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities J. Org. Chem. 1997, 62, 7512-7515
56. Darras, F. H.; Kling, B.; Heilmann, J.; Decker, M. Neuroprotective tri- and tetracyclic BChE inhibitors releasing reversible inhibitors upon carbamate transfer ACS Med. Chem. Lett. 2012, 3, 914-919